echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > In order to explore emerging R&D opportunities, the two pharmaceutical companies have reached a cooperation!

    In order to explore emerging R&D opportunities, the two pharmaceutical companies have reached a cooperation!

    • Last Update: 2021-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, with the vigorous development of the innovative drug industry, in order to seize the opportunity, more and more pharmaceutical companies have chosen the "marriage" of strong and powerful companies to jointly promote the development and commercialization of innovative drugs
    .
    Following the announcement of a strategic cooperation between CStone Pharmaceuticals and Hengrui Pharmaceuticals not long ago, it was reported on December 5 that Aide Biotech and Janssen China also signed a strategic cooperation memorandum.
    The two parties will jointly drive the innovative pharmaceutical ecosystem and help patients obtain greater benefits.
    , And will help "Healthy China 2030" at the same time
    .
    Public information shows that Yang Sen is a pharmaceutical subsidiary of Johnson & Johnson in China and a firm supporter of the "Healthy China 2030" plan
    .
    It is understood that the company has always been committed to meeting the growing medical and health needs of Chinese patients and families through R&D, introduction and production of high-quality drugs and innovative pharmaceutical solutions, and making unremitting efforts for their health and well-being
    .
    AdBio is a biopharmaceutical company engaged in the R&D, production and sales of molecular diagnostic products for oncology precision medicine, as well as providing related testing services
    .
    The company's products mainly include molecular diagnostic reagents for targeted drugs for tumor precision medicine and molecular diagnostic reagents for tumor chemotherapeutics.
    They are used to detect the relevant gene status of tumor patients and provide a reference basis for molecular diagnosis for clinicians to formulate precision medical treatment plans
    .
    At present, half of Janssen's medicines are the result of foreign cooperation
    .
    According to relevant reports in 2018, Johnson & Johnson maintains close cooperation with academic institutions and venture capital institutions in China, and is committed to finding next-generation cancer treatment options
    .
    Among them, the Global Lung Cancer Research Center in China is researching new drugs and medical equipment to find new ways to treat lung cancer, and at the same time researching consumer behavior to find better treatments to cure lung cancer
    .
    Therefore, the cooperation between Janssen and Aide Biology is also traceable
    .
    According to this memorandum of cooperation, the two parties will jointly create an end-to-end collaborative innovation service model, covering market access, doctor-patient education, research and development of new biomarkers, and the establishment of a big data platform
    .
    This cooperation will further empower patients' full-course management, while improving the accessibility of companion diagnosis and accelerating patient reimbursement, while optimizing the diagnosis of Janssen’s key target treatment areas including lung cancer and urothelial cancer.

    .
    At the same time, the two parties will explore and promote the access of innovative treatment plans under the "Hong Kong and Macau Medicines and Devices Access" and other relevant pilot policies for the access of innovative drugs and medical devices, so as to benefit patients as soon as possible and provide them with more treatment options
    .
    The so-called "Hong Kong and Macau medicines and equipment exchanges" policy was jointly issued by eight ministries and commissions in September 2020.
    The key tasks of this measure are to specify that designated medical institutions operating in nine cities in the Guangdong-Hong Kong-Macao Greater Bay Area use urgently clinically needed drugs that are already on the market in Hong Kong and Macao.
    , And medical devices that are urgently needed for clinical use, have been purchased and used by public hospitals in Hong Kong and Macau, and have advanced clinical applications, all of which are subject to approval by Guangdong Province
    .
    In addition, the two parties will also cooperate to achieve resource interaction and interconnection, carry out high-quality doctor-patient education on diseases, treatment and diagnosis, and coordinate to promote the integration of precision diagnosis and treatment to improve patient benefits
    .
    In the future, in optimizing clinical development, the two parties will explore emerging R&D opportunities, continue to explore, develop and provide transformative drugs and diagnostic solutions, and more accurately solve the treatment needs of many patients that urgently need to be met
    .
    For Janssen China, through this cooperation, it is conducive to continue to create more value for patients, medical staff and medical systems in China.
    Through the cooperation with Janssen China, Aide Biosciences will work with Janssen to accelerate the development of transformative treatment programs.
    Access and contribute to improving the benefit of patients
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.